Under the new Rebate Model effective January 1st, Covered Entities must “float” higher drug acquisition costs until rebates are received—straining budgets and forecasts. Without automation, slow submission cycles extend the time between purchase and reimbursement, leading to increased cash float that most health systems can't afford.

Organizing and preparing a variety of required data elements per claim will bottleneck teams. Expanded HRSA guidance now requires additional medical claims data per submission. Teams must pull information from multiple systems, reconcile formats, and ensure accuracy—where any missing element can lead to delays or denials.

With claims flowing through Beacon Channel Management and multiple data endpoints involved, maintaining visibility into outstanding rebates and payment timelines will be difficult without automation. For large health systems, this creates new coordination challenges across 340B, finance, and IT teams. For smaller organizations, the administrative lift may be prohibitive—leading some to consider excluding these drugs from their programs altogether.